Eli Lilly and InnoCare Pharma Sign License Deal Worth Up to $3.35 Billion

InnoCare Pharma disclosed on Thursday a research collaboration and license agreement with Eli Lilly, structured to reach as much as $3.35 billion in total payments. The arrangement pairs the Chinese biopharmaceutical company with the Indianapolis-based drugmaker, with the disclosed ceiling of $3.35 billion covering the full set of potential payments under the deal. The announcement was made by InnoCare Pharma, which described the transaction as both a research collaboration and a license agreement. Eli Lilly trades under the ticker $LLY. Beyond the maximum total value, the announcement did not specify the split between upfront payments, milestone payments, or royalties, nor did it name the particular therapeutic targets or disease areas involved. No financial terms other than the $3.35 billion total were provided, and no timeline for the collaboration was given. The deal represents one of the larger China-linked pharmaceutical partnerships announced in recent days, linking a Chinese biotech with a major United States pharmaceutical company.